
Pfizer currently distributes $0.43 per share quarterly, amounting to $1.72 annually. This means if their annual earnings per share fall below that figure, the payout ratio ventures into the realm of mathematical improbability. And recently, they have. Last month’s earnings report revealed a slight hiccup – a loss, actually – with earnings per share clocking in at a negative $0.29. This wasn’t due to any catastrophic failure of pharmaceutical innovation, mind you, but rather due to something called ‘asset impairment charges’ – roughly $4.4 billion worth. It’s a bit like the universe politely correcting Pfizer’s accounting, suggesting perhaps they’d overestimated the value of something. Full-year EPS landed at $1.36, a minor dip from the previous year’s $1.41. However, these impairment charges are non-cash items, which means they’re not actual money leaving the building, just a re-evaluation of what the building was worth in the first place. (It’s a bit like realizing your antique stamp collection is actually just a pile of colorful paper. Disappointing, but doesn’t immediately impact your ability to buy tea.)